Global Momelotinib tablets Market Strategic Research Report

Scope of the Report

The global Momelotinib tablets market size is predicted to grow from US$ 24.46 million in 2025 to US$ 813 million in 2032; it is expected to grow at a CAGR of 47.7% from 2026 to 2032.

Momelotinib tablets are an orally administered small-molecule Janus kinase (JAK) inhibitor primarily used for the treatment of myelofibrosis and other myeloproliferative neoplasm-related disorders. The drug selectively inhibits the JAK1 and JAK2 signaling pathways, thereby modulating abnormal cytokine signaling, reducing inflammatory responses, improving anemia-related symptoms, and suppressing abnormal hematopoiesis. As a next-generation JAK inhibitor, momelotinib demonstrates certain advantages in improving anemia-related parameters and is suitable for patients who have previously received JAK inhibitor therapy but experienced insufficient efficacy or concomitant anemia. The drug has entered clinical use and is being gradually adopted in the treatment of myelofibrosis.In 2025, global production of mobocertinib reached approximately 1.5 million tablets.

Momelotinib tablets, as a next-generation oral JAK inhibitor, are primarily used in the treatment of myelofibrosis and are positioned within the rapidly growing market for drugs targeting myeloproliferative neoplasms. In recent years, driven by increasing diagnosis rates of rare hematologic malignancies and rising demand for targeted therapies, the global JAK inhibitor market has continued to expand, with marketed products such as ruxolitinib accounting for a significant share of the market. Momelotinib tablets offer a potential differentiated advantage in improving anemia-related outcomes, making them a promising option for patients who have had insufficient response to prior JAK inhibitor therapies or present with concomitant anemia. However, the market is already dominated by well-established drugs, resulting in a highly concentrated competitive landscape. New entrants must achieve breakthroughs through clinical efficacy, long-term safety data, and pricing strategies. Therefore, future market growth will largely depend on indication expansion, clinical data validation, and commercialization progress.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Momelotinib tablets market?

What factors are driving Momelotinib tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Momelotinib tablets market opportunities vary by end market size?

How does Momelotinib tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Momelotinib tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg tablets
• 200 mg tablets

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Dosage form

• Tablet
• Film-coated tablet

Segment by Production Technology

• Generic
• Innovator

Segment by Application

• Allergic Rhinitis
• Chronic Spontaneous Urticaria (CSU)
• Bronchial Asthma
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Momelotinib tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU), Bronchial Asthma evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact